Deep Genomics

The company was started by CEO Brendan Frey in 2014; it has raised $237.2 million in funding to date, including $180 million from its most recent Series C round in 2021. The company is a developer of an AI-enabled RNA therapeutic discovery platform; its "AI workbench" focuses on the development of s...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Is it time for AI for drug discovery as a service?

Case Study | October 25, 2021

Despite the value of AI to the pharmaceutical industry in the drug discovery space, significant barriers to its adoption remain. One of the major barriers lies in developing the relevant AI capabilities to tackle questions around novel target identification, lead identification and optimization, ... Not part of subscription

Regulus Therapeutics

Company Profile | December 01, 2021

Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription

Pfizer partnering with Alex Therapeutics to develop nicotine-addiction DTx

News Commentary | February 08, 2022

Pfizer has partnered with Stockholm‑based DTx (digital therapeutics) maker Alex Therapeutics to deploy artificial intelligence (AI)‑based digital therapeutics. The Alex DTx platform combines cognitive‑based therapy and acceptance and commitment therapy with AI to offer personalized treatment plans. ... Not part of subscription